A recent report about the ability of acetyl-6-formylpterin (acetyl-6-FP, an MR-1 antagonist) to accelerate regression of liver fibrosis in mice [109] supports the concept of using inactive MR1 ligands in the treatment of liver diseases. Here, MR1 is linked to Hepatic fibrosis.